ArticleCureus2025
Breast Primary Follicular Lymphoma: Two Cases of a Rare Entity Treated With Radical Radiotherapy and Rituximab.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary lymphoma of the breast: A case report.Radiology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary breast lymphoma (PBL) is a rare form of non-Hodgkin's lymphoma (NHL), characterized by lymphoma primarily affecting the breast tissue and not seen anywhere else in the body. Follicular breast lymphoma, a distinct histological variant of NHL, manifests with an even greater rarity within the context of breast tissue. The optimal therapeutic approach for these tumors remains controversial. Two cases of follicular lymphoma of the breast are hereby reported. The patients, aged 58 and 56 years, presented at the institution with a breast lump. A biopsy was subsequently performed, yielding a diagnosis of follicular lymphoma. The subjects underwent a positron emission tomography (PET)-computed tomography (CT) scan, which revealed hypermetabolic uptake in the respective breast nodules, with no further alterations. Consequently, they were staged as stage IE. Patients were offered a course of radical radiotherapy with concomitant rituximab. PET-CT scans five months after treatment from both patients revealed a complete metabolic response. In conclusion, we emphasize the role of radiotherapy and rituximab in the management of follicular breast lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.